PharmaDrug Inc. has successfully completed the acquisition of Securedose Synthetics Inc. The transaction involved the acquisition of all issued and outstanding shares of SecureDose through a three-cornered amalgamation, making SecureDose a wholly-owned subsidiary of PharmaDrug. The arm’s length transaction marks a significant step for PharmaDrug in expanding its portfolio and capabilities in the pharmaceutical sector.
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), is pleased to announce that it has closed the previously announced acquisition (see press release dated October 27, 2023) of Securedose Synthetics Inc. (“SecureDose”). PharmaDrug acquired all of the issued and outstanding shares of SecureDose by way of a three-cornered amalgamation between Pharmadrug, SecureDose and a wholly-owned subsidiary of PharmaDrug (the “Transaction”). Following completion of the Transaction SecureDose became a wholly-owned subsidiary of PharmaDrug. The Transaction was an arm’s length transaction for the purposes of applicable securities laws.